Colchicine, a cheap anti-inflammatory drug commonly used to treat gout, does not reduce the severity of COVID-19 or avoid the risk of death from infection in inpatients and is open to the public. Find a pooled analysis of available evidence that has been journal RMD open..
In addition, the analysis shows that it is associated with an increased risk of side effects, especially diarrhea.
quick Observational study It has been suggested that colchicine may be a useful addition to the treatments available for COVID-19 infection, and it has already found that method. Clinical practice In some places.
To clarify its safety and efficacy, researchers are looking for relevant comparative clinical trial data on the use of drugs for the treatment of COVID-19 infections published by July 2021. I checked the research database.
Researchers wanted to know if colchicine reduced the risk of death, the need for ventilation assistance, hospitalization in the intensive care unit, and length of stay. And whether its use was associated with a particular side effect.
They applied a recommendation, evaluation, development, and evaluation grade (GRADE) approach to assess the quality of the evidence for each of these results.
Observational study, Laboratory research, Animal studies, and studies with less than 10 participants were all excluded.
Of the 69 full texts evaluated, 6 randomized controlled trials of 16,148 patients with different severity of COVID-19 were included in the pooled data analysis.
This is significant for mortality risk (6 studies), need for ventilation support (5 studies), hospitalization in intensive care unit (3 studies), length of stay (4 studies), or serious side effects (4 studies). Showed that there was no decrease. 3 studies) Between patients treated with colchicine and those who received only conventional supportive care.
Patients taking colchicine also had a 58% higher incidence of side effects and were nearly twice as likely to have diarrhea as those receiving supportive care.
The GRADE quality of the evidence was moderate in most of the findings investigated.
Researchers warn: “Our findings on colchicine need to be carefully interpreted as they include open-label randomized clinical trials. Analysis of efficacy and safety results is limited. [randomised controlled trials] In control intervention. “
However, they conclude that: “Colchicine does not reduce the risk of death of COVID-19 patients, the need for ventilation assistance, hospitalization in the intensive care unit, and length of stay. COVID-19 patients.”
Efficacy and Safety of Colchicine in COVID-19: A Meta-Analysis of Randomized Controlled Trials, RMD open, DOI: 10.1136 / rmdopen-2021-001746
British Medical Journal
Quote: The gout drug colchicine does not reduce the severity of COVID-19 or avoid the risk of death (2021, 22 November). -lessen.html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death Source link Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death
The post Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death appeared first on California News Times.